i3 Health

i3 Health


Best Practices in Nursing Management of Chemotherapy-Induced Peripheral Neuropathy

STATEMENT OF NEED Chemotherapy-induced peripheral neuropathy (CIPN) is a complication of cancer treatment that may impair quality of life and lead to treatment dose reductions or discontinuation in severe cases. In one study of 123 patients receiving taxane therapy for breast cancer, 17% required dose reductions because of CIPN (Bhatnagar et al, 2014). Whereas in some patients the symptoms of...
i3 Health

Challenges and Opportunities in Hodgkin Lymphoma

STATEMENT OF NEED Hodgkin lymphoma (HL) is a rare malignancy involving the lymph nodes and lymphatic system, with 8,500 new cases diagnosed and accounting for 1,050 deaths each year in the United States. In contrast with other cancers whose risk increases with age, the risk for HL increases in patients between 15 and 30 years of age, decreases during middle age, and is followed by another pea...
i3 Health

Challenges and Opportunities in Metastatic Gastric Cancer

STATEMENT OF NEED Gastric cancer is the third leading cause of cancer-related death worldwide. In the US, an estimated 27,510 new cases of gastric cancer are diagnosed annually, and 11,140 people die of the disease. Despite advances in prevention, diagnosis, and treatment, due to the molecular heterogeneity of gastric cancer, prognosis remains poor. The 5-year survival rate for all stages is ...
i3 Health

Current Challenges and New Opportunities in Follicular Lymphoma

STATEMENT OF NEED Of the estimated 74,680 new cases of non-Hodgkin lymphoma each year in the United States, approximately 35% are follicular lymphoma (FL), an indolent, difficult-to-treat B-cell malignancy. Most patients are diagnosed at an average age of 65 years. Despite the introduction of novel therapies during the past decade, complications such as delayed presentation and treatment and ...
Postgraduate Institute for Medicine and i3 Health

Current Trends and Future Directions in Targeted Therapies for Advanced Renal Cell Carcinoma

STATEMENT OF NEED Based on recent estimates, kidney cancer accounts for approximately 4% of all cancer diagnoses in the United States. An estimated 65,300 new cases are reported each year and more than 14,000 people die of the disease. Renal cell carcinoma (RCC), which comprises nearly 90% of all kidney cancers, is characterized by a lack of early warning signs, diverse clinical manifestation...
Penn State College of Medicine and i3 Health

Current Trends in the Management of Castration-Resistant Prostate Cancer

STATEMENT OF NEED Prostate cancer is the most common tumor type in men in the United States. Typically, androgen deprivation therapy is administered for progressive disease. However, castration resistance or unresponsiveness to androgen deprivation therapy or to antiandrogens frequently develops over time. The transition from castration-sensitive to castration-resistant disease has yet to be ...
i3 Health

Management of Cancer Pain: Current Guidelines

STATEMENT OF NEED Cancer patients often experience a range of symptoms that negatively impact their quality of life. Among the most debilitating is pain. Despite efforts to increase awareness, cancer pain is still underdiagnosed and undertreated and patients do not obtain complete relief. Although numerous management guidelines for cancer pain have been developed, most health care practitione...
i3 Health

Management of Venous Thromboembolism in Ambulatory Patients With Cancer

STATEMENT OF NEED Venous thromboembolism (VTE) is a common and potentially life-threatening complication in patients with cancer. There are two main types of VTE: deep vein thrombosis (DVT) and pulmonary embolus (PE), which can cause right heart failure, cardiopulmonary collapse, and death (Ozaki & Bartholomew, 2012). Patients who develop PE require hospitalization, increased oxygen requireme...
i3 Health

Management of Venous Thromboembolism in Hospitalized Patients With Cancer

STATEMENT OF NEED Venous thromboembolism (VTE), which consists primarily of deep vein thrombosis (DVT) and pulmonary embolism (PE), is a life-threatening complication in hospitalized patients with cancer, and is associated with a 2- to 6-fold increase in likelihood of death (NCCN, 2016). The mainstay of treatment is anticoagulation; however, since cancer patients with VTE have higher rates of...
i3 Health

Nursing Management of Bone Health in Patients With Cancer

STATEMENT OF NEED Many tumors, such as prostate, breast, lung, and multiple myeloma, affect bone health. Once cancer spreads to the skeletal system, the risk for pain, fractures, hypercalcemia, and nerve compression increases considerably. Several studies have shown that the use of antiresorptive agents such as bisphosphonates and monoclonal antibodies can reduce the morbidity of skeletal com...
i3 Health

Nursing Management of Cancer Treatment-Induced Cardiotoxicity

STATEMENT OF NEED Several studies reveal that certain cancer therapies adversely affect the heart and lead to various types of injuries, which often result in death. Adverse cardiac effects may occur immediately after cessation of therapy or, in some cases, years after the therapy has been discontinued. Often the cardiotoxicity presents in subtle ways, and a lack of awareness results in high ...
i3 Health

Nursing Strategies to Optimize Treatment Experiences in Hormone-Receptor Positive, HER2-Negative Metastatic Breast Cancer

STATEMENT OF NEED Breast cancer accounts for nearly 30% of cancer diagnoses among women in the United States, and is the second-leading cause of cancer death in this population. Although many women benefit from regular screening as well as earlier and improved treatment, approximately 10% present with metastatic disease, and 30% with no initial lymph node involvement eventually develop metast...
USF Health and i3 Health

Optimizing the Management of Advanced Cervical Cancer With Checkpoint Inhibitor Therapy

STATEMENT OF NEED There are an estimated 13,240 new cases of cervical cancer in the United States each year, and 4,170 people die of the disease. Due to screening and heightened awareness, deaths have declined during the past few decades. However, the malignancy continues to be a global health concern and is considered an epidemic in parts of the world. A significant proportion of patients de...
Postgraduate Institute for Medicine and i3 Health

Optimizing Treatment Experiences in Castration-Resistant Prostate Cancer: ONS 44th Annual Congress Complimentary Dinner Satellite Symposium

STATEMENT OF NEED Prostate cancer is the most common tumor type in men in the United States. Typically, androgen deprivation therapy is administered for progressive disease. However, castration resistance or unresponsiveness to androgen deprivation therapy or to antiandrogens frequently develops over time. The transition from castration-sensitive to castration-resistant disease has yet to be ...
i3 Health

Prevention of Medical Errors in Nursing Practice

STATEMENT OF NEED Medical errors are among the most common health-threatening mistakes that affect patient care, accounting for as many as 250,000 deaths per year in the United States (Makary & Daniel, 2016). Medical errors are considered a global problem, complicating a patient’s primary condition for which they needed medical attention. These errors can lead to adverse outcomes such as incr...
i3 Health

Understanding and Optimizing CAR T-Cell Therapy for Patients With B-Cell Malignancies

STATEMENT OF NEED Although the clinical outcomes of patients with B-cell malignancies such as diffuse large B-cell lymphoma and B-cell acute lymphoblastic leukemia have improved during the past decade, many continue to develop relapsed or refractory disease, representing a significant cause of morbidity and mortality. CAR T-cell therapy has been shown to produce significant antitumor response...
i3 Health

RXinsider, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps. RXinsider, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map.